Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Wall Street Zen

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently weighed in on FOLD. Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Thursday. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.78.

Amicus Therapeutics Trading Down 1.8%

Shares of FOLD stock opened at $8.33 on Friday. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -69.41 and a beta of 0.55. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The firm’s 50 day moving average price is $7.13 and its two-hundred day moving average price is $6.98.

Institutional Trading of Amicus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its stake in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,677 shares during the last quarter. Strs Ohio bought a new stake in Amicus Therapeutics during the first quarter valued at $30,000. PNC Financial Services Group Inc. increased its stake in Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Amicus Therapeutics during the first quarter valued at $53,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.